The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy

Paul Chan, Ching Bing Lee, Tz Shing Lin, Jiing Tang Ko, Wen Harn Pan, Ying Shiung Lee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

Original languageEnglish
Pages (from-to)1099-1104
Number of pages6
JournalAmerican Journal of Hypertension
Volume8
Issue number11
DOIs
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Pravastatin
Antihypertensive Agents
Safety
Placebos
Therapeutics
Cholesterol
Diet
Hyperinsulinism
LDL Cholesterol
HDL Cholesterol
Fasting
Triglycerides
Lipids
Drug Therapy

Keywords

  • Cholesterol
  • hypercholesterolemia
  • hypertension
  • pravastatin

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. / Chan, Paul; Lee, Ching Bing; Lin, Tz Shing; Ko, Jiing Tang; Pan, Wen Harn; Lee, Ying Shiung.

In: American Journal of Hypertension, Vol. 8, No. 11, 1995, p. 1099-1104.

Research output: Contribution to journalArticle

Chan, Paul ; Lee, Ching Bing ; Lin, Tz Shing ; Ko, Jiing Tang ; Pan, Wen Harn ; Lee, Ying Shiung. / The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. In: American Journal of Hypertension. 1995 ; Vol. 8, No. 11. pp. 1099-1104.
@article{73e883e900e5485381724dd53ba46295,
title = "The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy",
abstract = "To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20{\%} and -25{\%}, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5{\%}) while triglycerides slightly decreased (-8{\%}) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.",
keywords = "Cholesterol, hypercholesterolemia, hypertension, pravastatin",
author = "Paul Chan and Lee, {Ching Bing} and Lin, {Tz Shing} and Ko, {Jiing Tang} and Pan, {Wen Harn} and Lee, {Ying Shiung}",
year = "1995",
doi = "10.1016/0895-7061(95)00229-I",
language = "English",
volume = "8",
pages = "1099--1104",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy

AU - Chan, Paul

AU - Lee, Ching Bing

AU - Lin, Tz Shing

AU - Ko, Jiing Tang

AU - Pan, Wen Harn

AU - Lee, Ying Shiung

PY - 1995

Y1 - 1995

N2 - To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

AB - To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

KW - Cholesterol

KW - hypercholesterolemia

KW - hypertension

KW - pravastatin

UR - http://www.scopus.com/inward/record.url?scp=0028880638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028880638&partnerID=8YFLogxK

U2 - 10.1016/0895-7061(95)00229-I

DO - 10.1016/0895-7061(95)00229-I

M3 - Article

VL - 8

SP - 1099

EP - 1104

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 11

ER -